Clinical trials · California
Focal Segmental Glomerulosclerosis clinical trials in California
We’re tracking 8 recruiting focal segmental glomerulosclerosis studies with a site in California — including Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT07268638RecruitingPhase 2
Study of praliciguat for focal segmental glomerulosclerosis
This trial tests an investigational drug called praliciguat for people with FSGS, a kidney disease that causes scarring in the kidney filters. The goal is to see if praliciguat can help reduce protein in the urine and protect kidney function.
Chula Vista, CaliforniaAges 18 years+ - NCT07220083RecruitingPhase 3
A study of BI 764198 for people with FSGS kidney disease
This trial tests if a new medicine called BI 764198 can help people with a kidney condition called FSGS. It looks at whether the drug can reduce protein in the urine and protect kidney function.
Fremont, CaliforniaAges 12 years+ - NCT06500702RecruitingPhase 2
Study of three drugs for FSGS or minimal change disease
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
Orange, CaliforniaAges 16–75 - NCT02235857Recruiting
Device treatment study for children with focal segmental kidney scarring
This trial studies a medical device (the Liposorber LA-15) in children with focal segmental glomerulosclerosis (FSGS), a kidney condition that can cause heavy protein loss in the urine. It may help by improving disease control when standard treatments have not worked, were hard to tolerate, or can’t be used.
Loma Linda, CaliforniaAges Up to 21 years - NCT04065438Recruiting
Study of a blood-filter treatment for FSGS not responding to meds
This study looks at how well a specialized blood-filter device (the LIPOSORBER® LA-15) works for people with primary FSGS—especially when standard steroid and other medicines don’t work or can’t be tolerated. It may help reduce disease activity, particularly in people with kidney function that is still moderate or in those after kidney transplant.
Loma Linda, CaliforniaAges Up to 75 years - NCT05003986RecruitingPhase 2
Sparsentan for children with protein leaking kidney diseases
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
Los Angeles, CaliforniaAges 1–17 - NCT06466135RecruitingPhase 2
Study of WAL0921 for glomerular kidney diseases
This study tests a new drug called WAL0921 for people with certain types of kidney disease. The goal is to see if it can help protect kidney function.
Los Angeles, CaliforniaAges 18–75 - NCT01209000Recruiting
Study for children with new kidney protein loss
This study is for children (and some newly diagnosed patients) who have nephrotic syndrome—kidneys leaking a lot of protein. It aims to better understand the kidney condition (sometimes using biopsy) and support future care decisions.
San Francisco, CaliforniaAges Up to 80 years
Focal Segmental Glomerulosclerosis trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting focal segmental glomerulosclerosis studies listed above.
- Academic Medical Research Institute · 2 studies
- Cedars-Sinai Medical Center · 2 studies
- Loma Linda University Children's Hospital · 2 studies
- Alkermes Investigational Site
- Amicis Research Center
- Investigational Site
- Investigational Site Number 8400015
- Investigator Site #12
What taking part in a focal segmental glomerulosclerosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Focal Segmental Glomerulosclerosis trials in other states
Common questions
- Are there focal segmental glomerulosclerosis clinical trials in California?
- Yes. We're currently tracking 8 recruiting focal segmental glomerulosclerosis studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a focal segmental glomerulosclerosis study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a focal segmental glomerulosclerosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New focal segmental glomerulosclerosis studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.